Beam Therapeutics
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Employees
- 436
- Market Cap
- $2.1B
- Introduction
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients with Glycogen Storage Disease Type Ia (GSDIa)
- Conditions
- Glycogen Storage Disease Type Ia
- First Posted Date
- 2024-12-16
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Beam Therapeutics Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT06735755
- Locations
- ๐บ๐ธ
Clinical Study Site, Farmington, Connecticut, United States
A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)
- Conditions
- Alpha 1-Antitrypsin Deficiency
- Interventions
- Drug: BEAM-302
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Beam Therapeutics Inc.
- Target Recruit Count
- 106
- Registration Number
- NCT06389877
- Locations
- ๐ฌ๐ง
Clinical Study Center, London, United Kingdom
A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
- Conditions
- Lymphoblastic LeukemiaLymphoblastic LymphomaT-Cell Lymphoblastic Leukemia/Lymphoma
- Interventions
- Biological: BEAM-201
- First Posted Date
- 2023-06-02
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Beam Therapeutics Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT05885464
- Locations
- ๐บ๐ธ
Stanford University School of Medicine, Stanford, California, United States
๐บ๐ธColorado Blood Cancer Institute, Denver, Colorado, United States
๐บ๐ธUniversity of Chicago, Chicago, Illinois, United States
An Exploratory Investigation of a Supplement to Enhance Sleep Quality and Quantity
- Conditions
- Sleep HygieneSleepSleep Disturbance
- Interventions
- Dietary Supplement: Beam Organics Dream PowderDietary Supplement: Beam Organics Dream Powder Extra StrengthDietary Supplement: Placebo
- First Posted Date
- 2022-08-30
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Beam
- Target Recruit Count
- 64
- Registration Number
- NCT05521243
- Locations
- ๐บ๐ธ
Citruslabs, Santa Monica, California, United States
BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease
- Conditions
- Sickle Cell Disease
- Interventions
- Biological: BEAM-101
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Beam Therapeutics Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT05456880
- Locations
- ๐บ๐ธ
Phoenix Children's Hospital, Phoenix, Arizona, United States
๐บ๐ธChildren's Healthcare of Atlanta - Aflac Cancer and Blood Disorders Center - Egleston Hospital, Atlanta, Georgia, United States
๐บ๐ธHackensack University Medical Center, Hackensack, New Jersey, United States